Celltrion's anti cancer drugs hold 90% market share in C.America

Quick Summary:

The company’s biosimilar drug Truxima, a version of Roche’s blood cancer treatment Rituxan, has held over 90% market share in Costa Rica since its 2019 launch and has been supplied through national tenders for six consecutive years.

Celltrion’s autoimmune disease treatment Remsima, a biosimilar to Janssen's Remicade, also achieved over 90% market share in the Dominican Republic and Panama.

In Ecuador, Truxima and Herzuma have maintained a combined market share of 90%, while in the Dominican Republic, the two drugs together account for nearly 80% of prescriptions, according to the company.

---

More Pictures

---

Read Quick SummarySave Time

or

Article Details

Category: Economy

Markets: South KoreaCosta RicaDominicaDominican RepublicPanama

Topics: Treatment Cancer Costa Biosimilar Drugs Market Truxima Share Celltrion Roche’s Hold

Source Website Secure: Yes (HTTPS)

News Sentiment: Neutral

Fact Checked: Legitimate

Article Type: News Report

Published On: 2024-10-11 @ 10:41:41 (3 hours ago)

News Timezone: GMT +8:00

News Source URL: kedglobal.com

Language: English

Article Length: 189 words

Reading Time: 2 minutes read

Sentences: 16 lines

Sentence Length: 12 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © Korea Economic Daily

News ID: 22989716

View Article Analysis

About Korea Economic Daily

Main Topics: Economy

Official Website: kedglobal.com

Update Frequency: 14 posts per day

Year Established: 1964

Headquarters: South Korea

News Last Updated: 4 minutes ago

Coverage Areas: South Korea

Ownership: Independent Company

Publication Timezone: GMT +8:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #91

Publisher Details

Frequently Asked Questions